Penrhos Bio raise £1m Seed funding to accelerate development of the Remora™️ technology, and is joined as an investment partner by Eos Advisory.
Penrhos Bio has secured the second tranche of its £1m Seed funding round, and is pleased to welcome Eos Advisory as investment partners. This investment, including the first tranche in 2021, takes the business through to its Series A raise in 2023, and accelerates our business development pipeline.
for the press release see:
The first 3d printed audiology device has been launched by our partners Pro3dure at the 67th International Congress of Hearing Aid Acousticians hat benefits from
Working with our dental partners Pro3dure Medical, our anti biofilm platform (Remora™) has been incorporated into two of their key medical devices using their MSI®
Penrhos Bio joins with Pro3dure™ in a milestone licence deal that will bring the Remora™ technology into the dental space in 3D printed materials…
Penrhos Bio joins with Pro3dure™ in a milestone licence deal that will bring the Remora™ technology into the dental space in 3D printed materials…
Penrhos Bio is currently undertaking a Series A investment raise. This investment will accelerate our regulatory roadmap for the Remora™ technology and unlocks a number of higher value markets such as marine fouling and human healthcare…
Penrhos Bio joins with Pro3dure™ in a milestone licence deal that will bring the Remora™ technology into the dental space in 3D printed materials…